The deal size was increased to $250M from $175M and priced inside the $25.00-$27.00 target range. BofA, Evercore ISI, Goldman Sachs, Stifel, Wells Fargo, LifeSci Capital and H.C. Wainwright are acting as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics Halts Common Stock Offering
- Mineralys Therapeutics announces $175M common stock offering
- 3 Best Stocks to Buy Now, 9/2/2025, According to Top Analysts
- Jefferies expects Mineralys stock to trade up following AstraZeneca data
- Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones